Imagine a world where treating chronic obstructive pulmonary disease (COPD) isn't just about handing out inhalers—it's about unlocking personalized paths to better breathing for millions. That's the exciting, yet complex, reality we're stepping into today. But here's where it gets controversial: Are we ready to ditch one-size-fits-all treatments for something more tailored, or are we risking overcomplicating care for patients who just need straightforward help? Keep reading to discover how biologics are shaking up COPD management, and we'll explore the twists that might surprise you.
Over the last ten years, the way we handle COPD has quietly transformed. Traditionally, doctors relied heavily on inhaled medications like bronchodilators and corticosteroids to manage symptoms. Now, though, we're seeing a richer, biology-driven approach emerge. Experts now understand COPD not as a single condition, but as a group of different subtypes, each with unique patterns of inflammation. This shift encourages more personalized evaluations, stricter diagnostics, and the use of biomarkers—biological indicators in the blood or body—to customize treatments. For beginners, think of biomarkers like a blood test that reveals specific clues about your inflammation, helping doctors choose the best drug for your exact situation.
This change has sped up thanks to new targeted biologic therapies, especially for people with eosinophilic COPD—a subtype where white blood cells called eosinophils play a big role in lung inflammation. For many doctors, the 2024 FDA approval of dupilumab (brand name Dupixent) for this group was a game-changer, offering the first fresh treatment option in ages for those still battling frequent flare-ups, even with the best inhalers.1 This was quickly followed by mepolizumab's approval in 2025, and research into even more options is booming.2 Yet, as excitement builds, so do the practical dilemmas: Who exactly qualifies for these drugs? Do they work in everyday clinics as well as in trials? What happens when biomarkers fluctuate? And how do we overcome insurance hurdles to get patients the care they need?
And this is the part most people miss: It's not just about the fancy new drugs—it's about real-world barriers that could make or break patient outcomes. To dive into these issues, a panel of specialists, headed by Dr. MeiLan K. Han—a leading figure in pulmonary medicine at the University of Michigan—gathered at a clinical discussion hosted by HCPLive. They shared frontline insights from pulmonologists and airways experts on weaving biologics into COPD care. The talks covered tricky diagnoses of airway problems, setting practical thresholds for eosinophil levels, telling apart asthma-COPD overlap (where someone has traits of both conditions) from pure COPD, and shifting focus to 'treatable traits'—specific factors like frequent infections or particular inflammation patterns that can be targeted directly, rather than following rigid, step-by-step treatment ladders.
The discussion painted a picture of a field in flux: still built on basics like inhalers and rehab, but now enhanced by precise tools that could improve results for the right individuals.
Throughout the forum, doctors pointed out ongoing hurdles in COPD care, such as incorrect diagnoses, late referrals to specialists, improper inhaler use, and patients not sticking to their routines—these problems existed before biologics but greatly affect how well new therapies work.
One panelist shared, 'There are some of us who use dupilumab in patients where we haven't confirmed high eosinophils right now, thanks to steroid use... And I don't want to exclude those folks.' This raises eyebrows: Should we bend the rules based on clinical judgment, or stick strictly to lab numbers? It's a debate worth pondering.
A common thread was the push for better 'phenotyping'—detailed profiling—at the bedside. This involves closely analyzing eosinophils, patterns of flare-ups, imaging scans, and overall symptoms to figure out if a patient has pure COPD, asthma-COPD overlap, or a blend of inflammatory issues. Clinicians stressed that while eosinophils are a key guide, they shouldn't be the sole decision-maker, given their tendency to change over time and the need to consider the full patient picture.
When chatting about alternatives like roflumilast (a pill for severe COPD), another expert noted, 'The evidence shows it's the super frequent flare-up patients who gain the most. That said, I personally struggle with it because few of my patients can handle the side effects.' This highlights a controversial choice: Is it worth pushing a drug with tolerability issues, or should we prioritize patient comfort over potential benefits?
The group also delved into how biologics are applied in daily practice, with doctors outlining their go-to criteria for starting them—typically for highly symptomatic patients or those with recurrent exacerbations (sudden worsenings) despite top-tier triple inhaler therapy. They addressed the nitty-gritty challenges, including paperwork for approvals, insurance battles, infusion scheduling (since some biologics are given via IV), and the need for teamwork among pulmonologists, primary care doctors, pharmacists, and insurers.
One participant emphasized, 'Our primary care colleagues often lack deep training on COPD. They keep patients with flare-ups on oral steroids too long. A wide-reaching education effort to train frontline providers on spotting and referring cases early could really shift the disease's course.' This sparks another question: How much responsibility should primary care bear, and is broader training the key to reducing delays?
In the end, the key takeaway was a push toward more personalized, trait-focused COPD care: Use biologics when they fit, but always build on fundamentals like mastering inhaler techniques, engaging in pulmonary rehab (exercise programs to strengthen lungs), quitting smoking or avoiding triggers, and fostering ongoing doctor-patient relationships.
For a bit more context, treatable traits might include things like bacterial infections that can be treated with antibiotics, or specific allergies that biologics can target—examples that make this approach feel more accessible.
As we wrap up, it's clear we're at a crossroads in COPD treatment. What do you think—should biologics be the new standard for select patients, or do the hurdles make them more hype than help? Do you agree with using them off-label in certain cases, or is that too risky? Share your thoughts in the comments below—we'd love to hear your perspective on this evolving field.
References
Dupixent® (dupilumab) Approved in the U.S. as the First-ever Biologic Medicine for Patients with COPD. Regeneron Pharmaceuticals, Inc. September 27, 2024. https://www.globenewswire.com/news-release/2024/09/27/2954552/0/en/Dupixent-dupilumab-Approved-in-the-U-S-as-the-First-ever-Biologic-Medicine-for-Patients-with-COPD.html.
Johnson V. FDA Approves Mepolizumab for Eosinophilic COPD. News release. Article. HCPLive. https://www.hcplive.com/view/personalized-copd-treatment-lessons-biologic-trials-clinical-practice
Newsletter
Join thousands of clinicians staying current on new therapies, trial data, and expert insights—subscribe to HCPLive today.
